|Drug Name:||CLARINEX-D 12 HOUR|
(Schering logo)Manufactured for Schering CorporationKenilworth, New Jersey 07033 USA02/0629307601TU.S.
4,659,716; 4,863,931; 5,595,997; and 6,100,274Copyright © 2006, Schering Corporation.All rights reserved.
CLARINEX-D® 12 HOUR Extended Release Tablets is indicated for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis including nasal congestion, in adults and children 12 years of age and older.CLARINEX-D® 12 HOUR Extended Release Tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY).
CLARINEX-D® 12 HOUR Extended Release Tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients, or to loratadine.
Due to its pseudoephedrine component, it is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (MAO) inhibitor therapy or within fourteen (14) days of stopping such treatment (see Drug Interactions section).
It is also contraindicated in patients with severe hypertension, severe coronary artery disease, and in those who have shown hypersensitivity or idiosyncrasy to its components, to adrenergic agents, or to other drugs of similar chemical structures.Manifestations of patient idiosyncrasy to adrenergic agents include: insomnia, dizziness, weakness, tremor, or arrhythmias.
CLARINEX-D® 12 HOUR Extended Release Tablets should be used with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy.Central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension may be produced by sympathomimetic amines.